-transparent.png){kind=logo}
Haloperidol, a butyrophenone neuroleptic, is metabolically reduced in man, but not in rat and not in many other experimental animals. Here we present data that describes reductive haloperidol metabolism in guinea pigs in vivo. When haloperidol was injected intraperitoneally to guinea pigs, it was converted to reduced haloperidol so quickly that 1 hr after the injection the concentration of haloperidol was only about one fifth of that of reduced haloperidol. Dopamine metabolism was enhanced in the striatum after the administration of reduced haloperidol, but this enhancement could mostly be explained by oxidation of a small amount of reduced haloperidol back to haloperidol. The molecular mechanisms of haloperidol reduction should be further studied using guinea pigs as a model for human haloperidol metabolism.
E R Korpi, and
D T Costakos, and
R J Wyatt
January 1988,
Psychopharmacology,
E R Korpi, and
D T Costakos, and
R J Wyatt
January 1994,
Archives internationales de pharmacodynamie et de therapie,
E R Korpi, and
D T Costakos, and
R J Wyatt
April 1991,
Journal of clinical psychopharmacology,
E R Korpi, and
D T Costakos, and
R J Wyatt
April 1987,
Psychiatry research,
E R Korpi, and
D T Costakos, and
R J Wyatt
March 1973,
Berliner und Munchener tierarztliche Wochenschrift,
E R Korpi, and
D T Costakos, and
R J Wyatt
January 1993,
Progress in neuro-psychopharmacology & biological psychiatry,
E R Korpi, and
D T Costakos, and
R J Wyatt
December 1972,
Zeitschrift fur Laryngologie, Rhinologie, Otologie und ihre Grenzgebiete,
E R Korpi, and
D T Costakos, and
R J Wyatt
January 1972,
Patologia polska,
E R Korpi, and
D T Costakos, and
R J Wyatt
December 1965,
The Journal of physiology,
E R Korpi, and
D T Costakos, and
R J Wyatt
January 1963,
Acta tuberculosea et pneumologica Scandinavica,
